TransCode reports Phase 1a trial data for TTX-MC138 in solid tumors

September 28, 2026 8:04 AM

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) released updated clinical data from its Phase 1a trial of TTX-MC138, an anti-miR-10b therapeutic candidate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found